A team of U.S. and South Korean researchers have developed an AI model called MSI-SEER that can not only predict microsatellite instability-high (MSI-H) tumors based on tissue slides, but also flag “what it does not know.” “Have you ever asked ChatGPT anything, and the response was, ‘I don’t know?’” Cheong Jae-ho asked during an interview with BioWorld. “Probably not, and that is the problem with AI now.”
Activation of cannabinoid receptors in the peripheral nervous system may help treat inflammatory and gastrointestinal disorders as well as pain, and several full agonists have been reported but they present safety concerns. Partial agonists, such as those that activate receptors to 20%-50% of full activity, may be safer, yet so far such agonists have emerged serendipitously.
Daewon Pharm Co. Ltd. has disclosed tricyclic derivatives acting as reversible H+/K+-ATPase inhibitors reported to be useful for the treatment of gastroesophageal reflux disease.
Researchers from Opko Health Inc. and Entera Bio Ltd. recently presented preclinical pharmacokinetic data on OPK-8801003, an oral GLP-2 analogue developed for the treatment of short bowel syndrome.
C4X Discovery Holdings Ltd. has selected a preclinical candidate from its oral α4β7 integrin inhibitor program for the treatment of inflammatory bowel disease (IBD). The potent and selective α4β7 inhibitor supports once-daily dosing. Moreover, the company’s approach can be combined with other targeted therapies for patients with complex or refractory disease where existing approaches have failed to deliver sufficient control.
Haisco Pharmaceutical Group Co. Ltd. has identified pyridone derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of Crohn’s disease and ulcerative colitis.
Lactiga US Inc. has received an award from the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance the development of its secretory IgA (sIgA) antibody for inflammatory bowel disease (IBD).
Metabolic dysfunction-associated steatotic liver disease (MASLD) now affects over a third of adults worldwide. Its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), is a leading driver of cirrhosis, cancer and liver transplants while often coexisting with diabetes, obesity and cardiovascular disease.
Onco3r Therapeutics BV has obtained clinical trial application (CTA) approval by the Belgian regulatory authorities for its SIK3 inhibitor O3R-5671. A first-in-human trial will be conducted in Belgium and is expected to open enrollment in the coming weeks. Final data are expected in the first half of next year and will inform subsequent patient trials across a range of autoimmune diseases, which are planned to commence next year.
Omass Therapeutics Ltd. has entered into an exclusive collaboration and license agreement with Genentech Inc., a member of the Roche Group, for the rights to develop and commercialize Omass’ preclinical oral small-molecule program for inflammatory bowel disease.
RSS
